A–C. Mice were immunized by intradermal injection of CFA on days 0 and 21, and their lymph nodes were harvested on day 26. For each group, 3–6 mice were analyzed except as noted below. A. The Vγ4Vδ4+ cell numbers obtained from C57BL/6 vs. B6.MyD88−/− mice. Cells from the lymph nodes of 2 mice were pooled for the MyD88 naïve control. B. The percent of Vγ4+ cells co-expressing Vδ4. Cells from the lymph nodes of 3 mice were pooled for the MyD88 naïve control. C. The percent of IL-17A+ cells among Vγ4Vδ4+ cells. Only 2 mice were analyzed for the B6.MyD88−/− CFA treated group, and cells from the lymph nodes of 3 mice were pooled for the MyD88 naïve control. D–E. Mice were immunized as for A except immunizations were on day 0 and 14, and lymph nodes were harvested on day 20. D. The Vγ4Vδ4+ and Vγ1Vδ4+ cell numbers obtained from B6.TCRβ−/− vs. B6.TCRβ−/−IFNγ−/− mice. Error bars show s.d.; n.s.= not significant (p > 0.05). E. The percent of Vγ4+ or Vγ1+ cells co-expressing Vδ4 (left), and the percent of CD44-high Vγ4Vδ4+ or Vγ1Vδ4+ cells (right).